Skip to main content


Latest articles

01-02-2023 | Oncology | News | Article

FDA approves elacestrant, adds indication for pembrolizumab

Details of these breast and lung cancer decisions available here

30-01-2023 | Oncology | News | Article

EMA recommends new indication for darolutamide

Click through to find out more

27-01-2023 | Oncology | News | Article

Guideline for oncogene-addicted metastatic NSCLC issued by ESMO

Click through for the details of these evidence-based recommendations

26-01-2023 | Oncology | News | Article

Adding camrelizumab to chemo prolongs OS of patients with advanced nonsquamous NSCLC

An updated analysis of the CameL trial has shown a significant improvement in overall survival with the addition of camrelizumab to chemotherapy in treatment-naïve Chinese patients with advanced nonsquamous non-small-cell lung cancer.

23-01-2023 | Oncology | News | Article

ESMO releases guideline for metastatic NSCLC without oncogenic drivers

More information about this Clinical Practice Guideline available here

20-01-2023 | Oncology | News | Article

IL-7 genetic variant linked to ICI toxicity

A variant of the interleukin 7 gene is associated with an increased risk of immune-related adverse events in people with cancer receiving immune checkpoint inhibitor therapy, suggests research.